Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia
- 1 January 1987
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 11 (1) , 33-40
- https://doi.org/10.1002/pros.2990110105
Abstract
Plasma steroids were analyzed in 16 normal men and in 10 men with prostatic benign hyperplasia (BPH). The steroids measured by radioimmunoassay include pregnenolone, 17‐OH‐pregnenolone, dehydroepiandrosterone, androst‐5‐ene‐3β, 17β‐diol, testosterone, dihydrotestosterone, androstane‐3α 17β‐diol, androstane‐3β, 17β‐diol, estrone, and estradiol as well as their glucuronide derivatives. In addition, cortisol and the sulphoconjugated form of dehydroepiandrosterone were determined. Whereas the levels of pregnenolone, pregnenolone glucuronide and 17‐OH‐pregnenolone glucuronide are not different in the two groups, the levels of 17‐OH‐pregnenolone in the BPH group (0.87 ± 0.07 ng/ml) exceed by two‐fold (p < 0.01) those observed in normal men. Plasma dehydroepiandrosterone and androst‐5‐ene‐3β, 17β‐diol concentrations are markedly elevated in the BPH group (1.49 ± 0.23 and 0.55 ± 0.08 ng/ml vs the control groups 0.43 ± 0.11 and 0.31 ± 0.05 ng/ml, respectively). Since the plasma cortisol and pregnenolone levels are comparable in these two groups, our data suggest that the elevation of plasma 17‐OH‐pregnenolone, dehydroepiandrosterone, and androst‐5‐ene‐3β, 17β‐diol reflects an increase of adrenal 17‐hydroxylase activity in patients with BPH. A slight increase of the plasma dihydrotestosterone and androsterone glucuronide concentration is also observed in men with BPH, indicating an increase of 5α‐reduced androgen formation. We have also observed, in the BPH group, a 50% decrease (p < 0.01) of plasma glucuronidated androst‐5‐ene‐3β,17β‐diol, estrone, and estradiol levels, suggesting that the transformation of unconjugated estrogenic steroids into glucuronide derivative is inhibited in BPH patients. In summary, our data indicate that adrenal C‐19 steroids might be involved in the process of BPH. Furthermore, whereas the estrogen glucuronide formation is diminished in men with BPH, the prostatic androgen metabolism as reflected by plasma dihydrotestosterone and androsterone glucuronide concentrations seems to be increased.Keywords
This publication has 27 references indexed in Scilit:
- Decreased Urinary 5a-Androstane-3α,17β-Diol Glucuronide Excretion in Patients with Benign Prostatic Hyperplasia*Journal of Clinical Endocrinology & Metabolism, 1985
- Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the MaleJournal of the American Geriatrics Society, 1984
- Estrogen Receptor in Human Benign Prostatic HyperplasiaJournal of Urology, 1983
- Characterization and measurement of cytoplasmic and nuclear oestradiol-17β-receptor proteins in benign hypertrophied human prostateJournal of Endocrinology, 1982
- Concentration of Dihydrotestosterone and 3α-Androstanediol in Naturally Occurring and Androgen- Induced Prostatic Hyperplasia in the DogJournal of Clinical Investigation, 1979
- HORMONE BLOOD LEVELS AND THEIR INTER-RELATIONSHIPS IN NORMAL MEN AND MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH)Acta Endocrinologica, 1979
- Altered Metabolism of Androgens in Elderly Men with Benign Prostatic HyperplasiaJournal of Clinical Endocrinology & Metabolism, 1977
- ALTERED BLOOD ANDROGENS IN ELDERLY MEN WITH PROSTATE HYPERPLASIA.Journal of Clinical Endocrinology & Metabolism, 1975
- SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHYActa Endocrinologica, 1974
- Dihydrotestosterone in prostatic hypertrophyJournal of Clinical Investigation, 1970